GlassScriptPhysician profile
Douglas Alan Eller
NPI 1821032418
$1,607.00
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $610.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $520.77 | 2019-2020 | |
| Astellas Pharma US INC | $306.07 | 2019-2020 | |
| Pfizer INC. | $178.63 | 2019-2020 | |
| Aytu Biopharma, INC. | $156.22 | 2019-2020 | |
| Amgen INC. | $90.97 | 2019-2020 | |
| Janssen Biotech, INC. | $77.01 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $71.97 | 2019-2020 | |
| Boston Scientific Corporation | $58.37 | 2019-2020 | |
| Therapeuticsmd, INC. | $30.38 | 2019 | |
| Medtronic USA, INC. | $26.08 | 2019 | |
| Blue Earth Diagnostics | $24.02 | 2019 | |
| Dornier Medtech America, INC | $19.54 | 2019 | |
| Smith+Nephew, INC. | $18.33 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.52 | 2019 | |
| Coloplast Corp | $14.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Eller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.